• 1
    Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006; 368: 8967.
  • 2
    Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 9317.
  • 3
    Kim WR, Poterucha JJ, Kremers WK Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 96874.
  • 4
    Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 5
    Olivera-Martinez MA, Gallegos-Orozco JF. Recurrent viral liver disease (hepatitis B and C) after liver transplantation. Arch Med Res 2007; 38: 691701.
  • 6
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeaG-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 7
    Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine. Presented at th 57th Annual Meeting of the American Association for the Study of Liver Diseases, 27–31 October 2006. Boston, MA, USA.
  • 8
    Chang TT, Gish RG, De Mau R et al. AI463022 Behold Study Group. A comparison of entecavir and lamvudine for HBeaG-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 9
    Lai CL, Shouval D, Lok AS et al. AI463027 Behold Study Group. Entecavir versus lamivudine for patients with hbeag-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 10
    Tenney DJ, Pokorowski KA, Rose RE et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: A8889 (Abstract PL02).
  • 11
    Shakil AO, Lilly L, Angus P et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamvudine therapy for chronic hepatitis B infection. J Hepatol 2002; 36 (Suppl. 1): 122 (Abstract 433).
  • 12
    Samuelson A, Morgan M, Reynolds J et al. The use of entecavir following liver transplantation: pilot safety and tolerability data. Am J Gastroenterol 2008; 103 (Suppl. 1): S160.
  • 13
    Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 135661.
  • 14
    Leung N, Peng C-Y, Sollano J et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeaG(+) antiviral-naive Adults: 24 wk results (E.A.R.L.Y. Study). Hepatology 2006; 44 (Suppl 4): 554A.
  • 15
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 16
    Liaw YF, Leung N, Kao JH et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. The Asian–Pacific Association for the study of the liver. Hepatol Int 2008; 2: 26383.
  • 17
    Dan YY, Aung MO, Lim SG et al. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008; 2: 28495.
  • 18
    Yuan Y, Iloeje U, Li H et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese social security program. ISPOR 2008; 2: S1122.
  • 19
    Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10 (Suppl. 2): S74.